Browse through our GU Cast library going back to March 2020
Our Library
#ERUS26 Live Robotic Surgery Spectacular from Padua
A bumper episode bringing you some amazing highlights from the world's top live robotic urology meeting! We are once again at the EAU Robotic Urology Section Annual meeting, this year in Padua, Italy, featuring more than 50 live robotic urology surgeries, a large number of which are international telesurgeries - surgeons in Padua and patients in faraway countries. Get a close look at how this happens!
Ben & Sam's robot tour | #ERUS26
Check out Join Ben Challacombe (Guy’s Hospital, London), and Sam Davies (Mater Hospital, Brisbane), as they take Declan Murphy for a tour of the incredible robotic surgery technology at the EAU Robotic Urology Section (ERUS) meeting in Padua. The largest ever collection of robotic surgery devices at the world’s best urology live surgery meeting.
PLND for prostate cancer | Yes/No/Maybe?! With Briganti and Maurer
Pelvic lymph node dissection (PLND) - one of our perennial favourite and contentious topics on GU Cast. Today we have both Alberto Briganti (Milano, ITA), and Tobias Maurer (Hamburg, GER), in the studio. Two hugely experienced prostate cancer surgeons, both with huge expertise in PLND. Alberto's name synonomous with PLND due to the eponymous nomograms he has developed over the years. And Tobias with his pioneering experience in PSMA radio-guided PLND.
Journal Club | DETECT haematuria trial and the post-prostatectomy radiotherapy trials
Two great topics on the GU Cast Journal Club today. How should we image patients with haematuria (the DETECT trial, J Urol 2018), and what is the role of adjuvant vs salvage radiotherpay following radical prostatectomy (three great trials - RAVES, RADICALS and GETUG-AFU 17), see links below). Plus we welcome new GU Cast co-Editor Gaetan Devos, who recently joined us on Fellowship at Peter Mac, replacing Carlos Delgado.
Widespread welcome for new Aussie prostate cancer guidelines
The perennially thorny topic of prostate cancer screening has been very well addressed in the brand new Australian guidelines for the Early Detection of Prostate Cancer which we are delighted to highlight today. Pragmatic, progressive and patient-focused, are some of the comments we have read - great to hear! We have been very gratified to see the very positive reception which these guidelines have received, not just here in Australia, but also by other expert and patient groups around the world.
Advanced prostate cancer in a large urology group practice
Urologist Ben Lowentritt (Chesapeake Urology, Baltimore), pops into the studio today while passing through Melbourne. We chat about life in a large urology group practice (a huge part of urology service delivery in the USA), why there appears to be a drop in interest in Fellowship training, and his experience of managing advanced prostate cancer in a large urology group practice. Ben, who is also Secretary of the Large Urology Group Practice Association in the USA, has a lot of interest in gathering real world data from large urology group practices, and shares with us some data on the use of ARPIs in mHSPC which has recently been accepted for publication.
Journal Club | Randomised surgical trials that did not change practice!
Open vs partial nephrectomy, and open vs robotic prostatectomy - two large randomised trials that did not change surgical practice! Just as important to examine these in GU Cast Journal Club as to examine pivotal trials that did change practice. Today we discuss the EORTC Today we discuss the EORTC 30904 RCT looking at kidney cancer surgery (Eur Urol 2011), and the Brisbane randomised trial of open vs robotic prostatectomy conducted (Lancet 2016).
ARASEC - Rethinking clinical trial design
Welcome back Rana McKay! Renu was on a flight to Europe this week so Rana jumped into her seat in the GU Cast studio this week to have a chat about the intriguing ARASEC trial which she presented at the AUA Annual Meeting recently. Plus her thoughts on the ARACOG data presented at ASCO last month. And then a great chat with our other studio guest, Professor Renea Taylor, translational scientist at Peter Mac and Monash University, about the very interesting Early Onset Prostate Cancer project, an international collaboration which herself and Rana are both very involved with, looking at the reasons behind why younger men are turning up with aggressive prostate cancer.
Timing, touch & technique: Batting lessons for nerve-sparing radical prostatectomy | With Ash Tewari
Tips and tricks for nerve-sparing surgery, learned over 25 years of performing robotic radical prostatectomy. Today we are joined by Dr Ash Tewari, Chief of Urology at Mt Sinai (New York), to talk about his favourite topic - nerve-sparing surgery - and a little about his second favourite topic - cricket! Ash has been one of the world's foremost experts in robotic prostatectomy having been there at the very start when Mani Menon was developing the technique, and has studied the anatomy of nerve-sparing prostatectomy in fine detail. Today we chat through his thoughts on the optimal approach to nerve-sparing prostatectomy to deliver the best outcomes for our patients. Some surgical footage included on the YouTube version.
Berlin Masterclass | Advanced prostate cancer
Hot topics in a hot city!! Declan and Renu escaped from deep Winter in Melbourne and landed into the hottest day on record in Berlin!! We are here to help with the Astellas Global Prostate Cancer Masterclass, a wonderful two day meeting focussing on advanced prostate cancer. Delegates from all over the world and a top class local and International faculty. We catch up with great friends of GU Cast Stephen Freedland (Cedars-Sinai Medical Centre, Los Angeles) and Bertrand Tombal (UC Louvain, Brussels), to pick their brains on hot topics in this hot city.
EV-pembro in localised and advanced bladder cancer - a superb summary!
All you need to know about enfortumab vedotin (EV) & pembro in bladder cancer in 25 minutes! We are joined in studio by bladder cancer gurus Shilpa Gupta (Cleveland Clinic, USA) and Andrew Weickhardt (Austin Health, AUS) to get an update on the role of EV-pembro in both muscle-invasive localised bladder cancer, and metastatic bladder cancer
Testis cancer and miR-371 - all you need to know!
Yep it's been a buzz word in testis cancer for a while now, but with the read-out of the CLIMATE and SWOG 1823 trials in the past six months, we thought we better get ourselves updated on this exciting biomarker. We are joined in studio by testis cancer gurus Ben Tran (Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne), and online by Aditya Bagrodia (Urologist, UCSD, San Diego), to give us a bluffers guide to miR-371.
Journal club #8 | PROTECT and EV-301
Welcome to Episode 8 of our monthly GU Cast Journal Club! Today we focus on two very important papers in localised prostate cancer and metastatic bladder cancer. The landmark 15 year update of the PROTECT trial, published in NEJM in 2023, and the breakthrough EV-301 trial which heralded enfortumab vedotin in progressive metastatic bladder cancer, published in NEJM in 2021.
Bayer Apex comes to Melbourne!
Renu had been to an excellent Bayer Apex meeting in Europe in the past, so was very happy to hear Apex was coming to us for its first Asia-Pacific outing! A wonderful prostate cancer Faculty headlined by Neal Shore, Dan George, Derya Tilki, Fred Saad, Amit Bahl, Tamim Niazi to name but a few, plus almost 200 delegates from across the APAC region
Did PROTEUS just change Urology??
Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery.
ARASEC and Lead-in ADT - China focus
Two interesting papers caught the eye of our GU Cast China team this week; the first is the ARASEC trial which Dr Rana McKay read out in the Practice-Changing Plenary at the AUA Annual Meeting in Washington. This is an interesting comparison of ADT + darolutamide for mHSPC in a prospective US cohort, compared with an historical ADT-only control arm from CHAARTED. Interesting study design and interesting results. The second is the ADT Lead-In study led bu GU Cast China Editor, Dr Yao Zhu, which demonstrates how the timing of docetaxel chemotherapy in mHSPC can significnatly affect the likelihood of severe neutropenia. Your usual ho
Is Copper the new Gold??! Co-PSMA trial in European Urology
Now this is an interesting one, a new PSMA tracer which appears to greatly outperform 68Ga-PSMA-11 for biochemical recurrence. We discuss 64Cu-SAR-bisPSMA with Professor Louise Emmett (Nuclear Medicine Physician, Sydney), and Dr Matt Roberts (Urologist, Brisbane), which they compared head to head with trusty old 68Ga-PSMA-11 in the Co-PSMA trial, just published in European Urology.
EAU Prostate Cancer Guideline Update
One of our most popular podcasts every year is when we chat with EAU Guideline gurus Derya Tilki and Gianluca Giannarini about the latest updates to the EAU Prostate Cancer Guideline. It is a 250 word document which is updated in March every year and changes are eagerly awaited around the world. We catch up with Derya (Vice Chair of the Prostate Cancer Guidleine Committee) in person in Melbourne, and with Gianluca (Vice-Chair of the EAU Guideline Office) online, about the latest updates. We also chat with Gianluca about the work of the Guideline Dissemination Committee which he has Chaired for a number of years.
Journal club #7 | proPSMA and Penile Fractures(!)
Democracy in action! This month's GU Cast Journal Club papers were chosen by an audience vote at our GU Cast Live Event at EAU in London. Therefore today we focus on first, the landmark proPSMA paper which established the superior accuracy of PSMA PET/CT for staging unfavourable intermediate and high-risk prostate cancer (Lancet 2020). Then for something completely different, we dig out a paper called "Penile fractures - the merry price of Christmas", published in BJUI 2020. Thanks very much to our live audience for this one!
ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari
The trial they said would never be done! Huge congrats to the Alliance for Clinical Trials in Oncology who have recently opened the ASPIRE trial, a phase III randomised trial of ADT + apalutamide (doublet), vs ADT + apalutamide + docetaxel chemotherapy (triplet) for men with mHSPC. 1200 men will be recruited from more than 300 sites across the US with many sites already open and recruiting. This is the key trial which will answer the question of whether there is an overall survival benefit of adding chemo to the ADT/ARPI doublet which we all agree is standard of care.
